在多巴胺激动因子和对抗因子诱导的运动障碍症中,共享GABA传播病理
Yoshifumi Abe1, Sho Yagishita2, Hiromi Sano3
1Division of Brain Sciences, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo 160-8582, Japan.
Cell reports. Medicine
|September 29, 2023
概括
障碍运动,来自帕金森病的非自愿运动.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 失动症,以非自愿的运动为特征,可能是由于长期使用多巴胺相关药物而产生的.
- 帕金森病中的LID (L-DOPA诱导的动力障碍) 和精神分裂症中的TD (迟迟动力障碍) 尽管有不同的致病原体,但症状相似.
- 这些不同的条件的潜在共享机制仍然不清楚.
研究的目的:
- 确定L-DOPA诱导的运动障碍症 (LID) 和晚期运动障碍症 (TD) 的共同结构基础.
- 研究囊泡性胺黄油酸转运体 (VGAT) 在运动障碍的发展中的作用.
主要方法:
- 磁共振成像 (MRI) 用于宏观查.
- 超分辨率显微镜用于微观识别结构变化.
- 在小鼠模型中进行基因操纵,以评估VGAT过度表达的必要性和充分性.
主要成果:
- 在LID和TD模型小鼠中确定了条状中等脊状神经元的扩大轴突终端.
- 发现VGAT的状过度表达对于建模这些结构变化是必要和充分的.
- 已经证明,VGAT水平可以调节功能和行为变化的功能障碍症模型.
结论:
- 降低2型多巴胺受体信号传递和重复的多巴胺波动是VGAT过度表达和运动障碍的常见原因.
- 减少多巴胺波动可以通过降低VGAT调节来挽救运动障碍病理.
- VGAT是药物诱导运动障碍的发展中的关键调解者.
相关概念视频
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
367
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
367
01:24Parkinson's Disease: Treatment
292
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
292
01:15Parkinson's Disease: Overview
590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
446
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
446
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
709
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
709
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K